Search PubMed⌕ Search

PubMed · 318115

[Levamisole as an immunostimulating factor].

Abstract

Levamisole--(L)--1-2, 3, 5, 6--tetrahydro-6- phenylimidazo (2, 1-b)-- thiazol monohydrochloride, a simple chemical, first introduced as a broad spectrum antihelmintic , has been recently on the list of the nonspecific active immunostimulants together with BCG, Corynebacterium parvum, polyribonucleosides and transfer factor (TF). This, however, is oversimplification and may cause some confusion because levamisole, in contrast to the so-called immunostimulants, does not stimulate immunity above the normal level in man or prevent the primary growth of most experimental tumors in immunologically normal animals. Levamisole acts as an antianergic chemotherapeutic agent as it restores cell-mediated immunity in immunodepressed patients and prolongs the remission period. It even increases the number of long-term survivors when used as an adjunct to cytoreductive therapy in several animal cancer models. Levamisole is rapidly absorbed from the gastrointestinal tract and from injection site and is very well distributed in all tissues. Levamisole increases phagocytosis by polymorphonuclear cells or macrophages when added to these cells or given to donor animals and humans. The effect was pronounced on hypofunctional cells from patients and it was weak or absent on cells from normal donors. Chemotactic responsiveness of polymorphonuclear cells and monocytes from patients with defective leucocyte motility could be enhanced by levamisole added in vitro or given in vivo. The leucocyte migration inhibition in response to antigenic stimulation could be restored when levamisole was administered to anergic patients or added to their cells in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Smogorzewska. 1979. [Levamisole as an immunostimulating factor].. https://pubmed.ncbi.nlm.nih.gov/318115/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response.

Single-stranded RNA oligonucleotides containing an immunostimulatory motif (immunostimulatory RNA [isRNA]) are potent inducers of interferon-alpha via the Toll-like receptor 7. We investigated the effect of isRNA on the development of an immune response. We show that isRNA activates dendritic cells and induces production of Th1-type cytokines both in vitro and in vivo. Cytokine production led to bystander activation of T and B cells. We further demonstrate that isRNA triggers the generation of antigen-specific cytotoxic T cells and of an IgG2a-biased antibody response to antigen in a sequence-dependent manner. In summary, we provide evidence for the first time that isRNA oligonucleotides can simultaneously activate the innate and adaptive arms of the immune system.

Adjuvants, Immunologic↗

Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

Dendritic-tumor heterokaryons generated by electrofusion are highly immunogenic. In animal studies, a single vaccination was therapeutic for tumors established in the lung, skin, and brain. However, effective therapy required a third signal which could be provided by exogenous IL-12 or the agonistic anti-OX-40R monoclonal antibody (mAb). In this study, we investigated the mechanism and mode of actions of these two seemingly distinct adjuvants. In immunotherapy of the MCA205 sarcoma, administration of the neutralizing anti-IL-12 mAb nearly completely blocked the adjuvant effect of IL-12, but had minimal inhibitory effects on anti-OX-40R mAb. By contrast, in vivo administration of the antagonistic anti-OX-40L mAb inhibited the adjuvant effects of both IL-12 and anti-OX-40R mAb. Thus, a common pathway of endogenous OX-40 interaction is critical for the development of a therapeutic immune response. Analysis of the third signal mechanism revealed that in the absence of an adjuvant, vaccination with fusion hybrids led to IL-10 production without eliciting IFN-gamma secreting cells. The addition of IL-12 to vaccination suppressed IL-10 production and initiated sensitization of specific IFN-gamma secreting cells, resulting in a type 1-like antitumor immunity. These findings underscore the significance of the third signal in the design of dendritic cell-based cancer vaccines.

Adjuvants, Immunologic↗